Filter by:

Reset Filter
  • Life Sciences
Showing 13 - 24 of 57

Expert Network for Women in Healthcare and Life Sciences

This network connects women economists and academics working on healthcare and life sciences topics and offers an opportunity to learn about expert witness work.


Bringing New Science to Market

Sean Nicholson of Cornell University will speak at this event about innovation, adoption, and policy challenges in the healthcare industry.


ASHEcon 2023: The Annual Conference of the American Society of Health Economists

Caitlyn Fleming will speak at this annual event about the varied settings in which health economists contribute expertise.


21st Annual International Industrial Organization Conference (IIOC)

Cornerstone Research affiliated experts will be honored and present at this annual conference in Washington, DC.


Life Sciences Capabilities

From initial strategy through deposition and trial, clients have used our findings in hundreds of matters involving the life sciences industry.


Intersection of Intellectual Property and Competition Policy in Recent Cases

The authors discuss high-profile cases in the EU and US that concern IP rights and competition policy.


Why Curve-Fitting Cannot Be Used to Show Causation or Estimate Impact

Iain Cockburn discusses the problems with curve-fitting methodology in economic analysis in this Westlaw article.


Evaluating Innovation Theories of Harm in Merger Review: Economic Frameworks and Difficulties

The authors discuss recent life science cases that deal with innovation theories of harm, and what economic models can be useful in reviewing proposed mergers in this space.


Federal Trade Commission v. 1-800 Contacts

The Second Circuit Court of Appeals overturned an FTC decision regarding trademark enforcement against online competitors.

Press Release

Cornerstone Research Staff and Experts Submit Comments to Multilateral Pharmaceutical Merger Task Force

Comments emphasize the need for the FTC to consider the varied effects of mergers on innovation.


Alleged Failure to Disclose Drug Safety Issues

Cornerstone Research was retained by a pharmaceutical company facing securities litigation after it withdrew a drug from the market because of safety concerns.


ICC Arbitration Involving Commercially Reasonable Efforts to Develop and Commercialize a Drug

An ICC arbitration tribunal determined that the claimant did not materially breach its license agreement with the respondent, leaving the agreement in full effect.

How can we help you?

If you are looking for a publication not on our website, contact us.